Adenocarcinoma of Colon Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Adenocarcinoma Colon / Colon Adenocarcinoma / Adenocarcinoma of the Colon

Indication	Status	Phase
DBCOND0060083 (Adenocarcinoma of Colon)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01703910	Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic	Treatment	Capecitabine (DB01101) Cetuximab (DB00002) Cisplatin (DB00515) Dasatinib (DB01254) Docetaxel (DB01248) Doxorubicin (DB00997) Erlotinib (DB00530) Etoposide (DB00773) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Mitomycin (DB00305) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pemetrexed (DB00642) Raltitrexed (DB00293) Sorafenib (DB00398) Topotecan (DB01030) Vinorelbine (DB00361)
NCT00032110	Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer	Treatment	Erlotinib (DB00530)